Harry Raftopoulos

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.4K citations · Full text

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology · 2016 · 1.4K citations

Oncology, Metronomic Therapy, Pathology +7

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

David Warr, Paul J. Hesketh, Richard J. Gralla et al. · Journal of Clinical Oncology · 2005 · 464 citations

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia VanDam Sequist et al. · Journal of Thoracic Oncology · 2018 · 175 citations

Advanced Nsclc, First-line Therapy, Medicine +9

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Jørn Herrstedt, Hyman B. Muss, David Warr et al. · Cancer · 2005 · 118 citations · Full text